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Abstract The identification of molecular signatures pre-
dictive of clinical behavior and outcome in brain tumors has
been the focus of many studies in the recent years. Despite
the wealth of data that are available in the public domain on
alterations in the genome, epigenome and transcriptome of
brain tumors, the underlying molecular mechanisms leading
to tumor initiation and progression remain largely un-
known. Unfortunately, most of these data are scattered in
multiple databases and supplementary materials of publica-
tions, thus making their retrieval, evaluation, comparison
and visualization a rather arduous task. Here we report the
development and implementation of an open access
database (BTECH), a community resource for the deposi-
tion of a wide range of molecular data derived from brain
tumor studies. This comprehensive database integrates
multiple datasets, including transcript profiles, epigenomic
CpG methylation data, DNA copy number alterations and
structural chromosomal rearrangements, tumor-associated
gene lists, SNPs, genomic features concerning Alu repeats
and general genomic annotations. A genome browser has
also been developed that allows for the simultaneous
visualization of the different datasets and the various
annotated features. Besides enabling an integrative view
of diverse datasets through the genome browser, we also
provide links to the original references for users to have a
more accurate understanding of each specific dataset. This
integrated platform will facilitate uncovering interactions
among genetic and epigenetic factors associated with brain
tumor development. BTECH is freely available at http://
cmbteg.childrensmemorial.org/.
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Introduction
Central nervous system (CNS) tumors, including brain and
spinal cord tumors, have an estimated incidence rate of
18.71 cases per 100,000 person-years (American Brain
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Tumor Association http://www.abta.org/). In children under
age 15, CNS tumors are the leading cause of solid tumor
death (Jemal et al. 2008). CNS tumors can be classified
based on tumor location and histology. From the 2009
statistical reports of the Central Brain Tumor Registry of
the United States (CBTRUS), the majority of primary CNS
tumors are meningiomas (33.4%), glioblastomas (17.6%)
and astrocytomas (7.4%). Currently, diagnosis and treat-
ment of brain tumors are heavily dependent upon tumor
histology, albeit brain tumors sharing the same histological
features often display variable drug response and clinical
behavior. These differences have been shown to be due to
numerous genetic and epigenetic aberrations occurring
during brain development (Zlatescu et al. 2001; Mueller et
al. 2002; Brennan et al. 2009; Gravendeel et al. 2009).
Since cancer development and progression result from an
accumulation of genetic and/or epigenetic alterations
(Vogelstein and Kinzler 1993), a comprehensive under-
standing of the molecular mechanisms underlying these
events is needed for development of more effective
treatment regimens. Much effort has been made to discover
genetic and epigenetic events underlying brain tumor
development, including a number of comprehensive studies
aimed at uncovering alterations in gene expression, DNA
methylation, DNA copy number alterations and/or
chromosomal rearrangements.
Coordinated efforts from various centers and institutes
have been taken to address the genomic changes involved
in human cancers. The Cancer Genome Atlas (TCGA,
http://www.cancergenome.nih.gov) has been providing a
significant amount of datasets, both on gene expression and
DNA methylation, for glioblastoma multiforme (GBM).
The Repository of Molecular Brain Neoplasia Data (REM-
BRANDT, http://caintegrator-info.nci.nih.gov/) provides
molecular research as well as clinical trials data on brain
tumors including gliomas. The REMBRANDT site also
provides tools to analyze clinical and experimental data
across multiple clinical trials and studies.
In addition, a number of studies on brain tumors have
generated large amounts of research data. For gene
expression studies, both sequencing- and hybridization-
based approaches have been utilized to identify molecular
markers for the sub-classification of brain tumors, including
Serial Analysis of Gene Expression (SAGE) and multiple
expression microarray platforms. In addition, a number of
gene expression studies have been conducted to correlate
transcript profiles of particular brain tumors with their
clinical behavior, response to particular drugs, or recurrence
incidences (Freije et al. 2004; Bandres et al. 2005; Hegi et
al. 2005; Hoelzinger et al. 2005; Rich et al. 2005; Verhaak
et al. 2010). These studies have yielded a number of
candidate genes that might prove valuable as prognostic
markers and therapeutic targets.
Epigenetic modifications, and DNA methylation in partic-
ular, have been shown to be involved in tumor initiation,
progression and response to drugs (Hegi et al. 2005; Smith et
al. 2007). Methylation of DNA can suppress gene transcrip-
tion either by preventing the binding of transcription factors
(Kim et al. 2003), or by enabling the binding of chromatin
repressors (Bird and Wolffe 1999). Large methylation data-
sets have been generated in an effort to develop the
methylation landscape of normal human brain (Rollins et
al. 2006; Schumacher et al. 2006; Wu et al. 2010).
Alu retrotransposons, the most prevalent repetitive
element in the human genome at 1.2 million copies, have
also been associated with the development of various
tumors (Lin et al. 1988; Chen et al. 1995; Miki et al.
1996). In addition, Alu family sequences may disrupt the
normal splicing pattern of a gene (Lev-Maor et al. 2003).
Approximately 8,000 Alu elements have been predicted to
have the potential to become exonized (Sorek et al. 2004).
In addition, the continued amplification of Alu family
sequences has given rise to insertion polymorphisms within
human populations (Batzer et al. 1995; Xing et al. 2009).
Lastly, DNA copy number alterations, both losses and
gains, are commonly observed in tumors and they are
bound to affect gene expression (Taylor et al. 2005;
Deshmukh et al. 2008).
Uncovering the molecular mechanisms underlying devel-
opment and progression of brain tumors requires seamless
integration of large genomic, epigenomic and transcriptomic
datasets. Large amounts of data have been generated in
numerous studies using various techniques, but the resulting
datasets are typically in different formats and often not easily
retrievable. Here we report the development of a database,
Brain Tumor Epigenomics/genomics Database at Children’s
Memorial Hospital (BTECH), designed to store and to
facilitate integration of genomic, epigenomic and transcrip-
tomic datasets derived from brain tumor studies. A genome
browser has been installed to allow simultaneous visualiza-
tion of genomic, epigenomic and transcriptomic features. The
BTECH database contains manually curated datasets
extracted from publications and various other public resour-
ces as well as up to date DNA methylation data generated in
our laboratory from normal brain and brain tumor tissues. We
anticipate that BTECH will prove invaluable to investigators
conducting genomic, epigenomic and/or transcriptomic anal-
yses of brain tumors in their pursuit of the molecular
mechanisms underlying development and progression of
these tumors.
Data Acquisition and Processing
BTECH harbors a wide range of molecular datasets on—or of
relevance to—brain tumors, including gene expression, DNA
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methylation, DNA copy number alterations (gains and losses)
and structural chromosomal alterations, lists of genes of special
interest such as cancer or brain tumor related, and differentially
expressed in the brain or in brain tumors, manually curated
from public datasets. In addition, BTECH includes general
genomic annotations as well as specific data on subsets of Alu
elements, including data on insertional polymorphism, tran-
scription and methylation. These are listed in Table 1 along
with pertinent information concerning the datasets.
(i) Gene Expression Datasets
To compile a collection of gene expression profiles
from various brain tumor studies, queries were first
conducted against either Entrez PubMed (http://www.
ncbi.nlm.nih.gov/Literature/) or the NCBI Gene
Expression Omnibus (GEO; http://www.ncbi.nlm.nih.
gov/geo/index.cgi). The queries for GEO were
conducted with “brain tumor” as the keyword and
“Homo sapiens” as the organism. Given the wide range
of study purposes and experimental designs, only
datasets using surgical tumor samples or drug-treated
tumor cells lines were selected. In total, thirteen
expression datasets were downloaded, derived from
105 different types or sub-types of brain tumors as well
as from brain tumor cell lines (Freije et al. 2004;
Bredel et al. 2005; Dong et al. 2005a; Ma et al. 2005;
Pachiappan et al. 2005; Taylor et al. 2005; Bredel et al.
2006; Lee et al. 2006; Sun et al. 2006; Tso et al. 2006;
Turkheimer et al. 2006; Donson et al. 2009). In
addition, a large Serial Analysis of Gene Expression
(SAGE) brain tumor dataset derived from seventy three
SAGE libraries (Boon et al. 2002) was retrieved from
GEO. Altogether these datasets encompass 937 brain-
related biological samples (Table 1). Each downloaded
SOFT file was further processed (Supplementary
Table S1) and the final values were stored in BTECH.
Gene expression data on GBM from TCGA were
downloaded from the TCGA data portal site (http://www.
cancergenome.nih.gov/dataportal/data/about/, total 369
gene expression and 148 DNA methylation datasets as
of September 30, 2010). For each dataset, three levels of
data are available from TCGA (raw, normalized, and
interpreted). Since the interpreted data were generated
by merging the normalized data with the annotation
data, which provide the most information, this level of
data was downloaded. For the BTECH’s purpose of data
integration, a total of 80 samples with both gene
expression and DNA methylation data were selected.
The associated gene expression and DNA methylation
data are stored in BTECH, together with the available
clinical information for these samples, which can be
accessed from BTECH as well.
The REMBRANDT site (https://caintegrator.nci.nih.
gov/rembrandt/) not only provides molecular research as
well as clinical trials data on gliomas, but also provides
tools to analyze clinical and experimental data across
multiple clinical trials and studies. Because of the
complication of the clinical information and the integrity
of their analysis, datasets from this study are not
included in BTECH. Instead, a hyperlink is provided
for further reference.
We also obtained expression data from Gene
Expression Atlas2 provided by the Genomics Insti-
tute of the Novartis Research Foundation (human
reference sequence NCBI Build 36.1). In this study
the expression patterns for thousands of protein-
coding genes as well as poorly characterized genes
were examined (Su et al. 2004). From this study we
downloaded the expression profile of 79 different
normal human tissues including brain tissues from
Table 1 Data contents in BTECH (as of October 2010)
Gene expression
• Data generated with Affymetrix platforms and SAGE
• 13 datasets
• 73 SAGE libraries
• 105 different types of brain tumors and cell lines
• 937 biological samples
• 79 human normal tissues
DNA methylation
• Data generated with microarray-based techniques, methylation
sensitive enzyme-based sequencing, and bisulfate conversion
• Including normal brains and brain tumors
• Methylation levels of 38 Mb genomic regions
• 1.9 million CpG methylation values from 12 different tissues
as reference
• 80 datasets with gene expression data from same GBM samples
• 31,178 Alu elements and their 5′ flanking sequences from disease-
free brain tissues, primary non-aggressive, primary aggressive, and
recurrent pediatric ependymomas
Chromosomal alteration
• Data generated with aCGHs and SNPchips
• 68 ependymoma patients, 54 glial tumors, 178 gliomas
• DNA recombination rate from decode, Marshfield, Genethon
Genes of interests
• 2,722 tumor related genes
• 242 brain tumor related genes
• 321 brain tumor differentially expressed genes
Repetitive elements
• Annotation for 1,181,020 Alus
• 8,273 prone to exonized Alus
• 553 polymorphic Alus
General annotation
• Alu, SNP, CpG islands, Entrez genes, RefSeq mRNA, gene 3-frame
translation, microRNA
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such areas as cerebellum, cortex, medulla oblongata,
pituitary, pons, and temporal lobe.
(ii) DNA Methylation Dataset
Several large-scale DNA methylation datasets on
human normal brain or brain tumors have been made
public in the past few years (Rollins et al. 2006;
Schumacher et al. 2006; Wu et al. 2010). The
methylation datasets were retrieved from the publica-
tions of these studies. Moreover, as part of the Human
Epigenome Project, the DNA methylation profiles of
chromosomes 6, 20, and 22 were also generated; these
were obtained from multiple samples derived from a
total of 12 different tissue types (Eckhardt et al. 2006).
Although brain tissue was not included in this study,
the methylation data might prove valuable as reference
for future studies. Therefore, their datasets were down-
loaded as well (2006 release). As these datasets were
generated using different techniques, four sets of perl
scripts were written in order to make the methylation
datasets compatible with one another and also with the
BTECH genome browser (Supplementary Table S2).
As aforementioned, methylation data from TCGA
on GBM were downloaded from the TCGA data portal
site. A total of 80 samples with both DNA methylation
and gene expression data were selected. The
corresponding DNA methylation and gene expression
data, together with the clinical information for these
samples, are available from BTECH.
In addition, a high-throughput sequence-based strat-
egy was developed that enables simultaneous determi-
nation of the methylation status of thousands of CpG
sites localized within and in the 5′ flanking genomic
region of over 30,000 Alu retrotransposons dispersed
throughout the genome (Xie et al. 2009). This is of
special relevance given that hypomethylation of repet-
itive elements has been shown to be strongly associated
with cancer progression and poor clinical outcome
(Cho et al. 2007; Estecio et al. 2007; Roman-Gomez et
al. 2008). Hence, Alu repeats may prove invaluable as
reporters of epigenomic alterations during tumor
development and progression. Several ependymoma
tumor specimens—including primary non-aggressive,
primary aggressive, and recurrent tumors—and disease-
free brain tissue samples were investigated using the
technique discussed above (Xie et al. 2010). The
resulting methylation datasets from all these samples
are stored in BTECH, hence easily retrievable. To
preserve the integrity of the data and the sample set,
they are listed under a separate category, namely
“Soares’ Lab Methylation Data”, with separate tracks
for individual tumor samples. The results from this
dataset can be visualized through the genome browser
(Fig. 1).
(iii) Chromosomal Alteration Dataset
DNA copy number alterations including both gains
and losses are frequently associated with tumor
initiation and/or tumor progression (Brito-Babapulle
and Atkin 1981; Whang-Peng et al. 1982). Such
alterations might result in decreased expression of a
tumor suppressor gene or in increased expression of
an oncogene. Three such datasets have been generat-
ed for brain tumors in recent years. One study used
matrix-based comparative genomic DNA microarray
to analyze chromosomal alterations in 68 ependymo-
mas (Mendrzyk et al. 2006). Another study used
cDNA microarray-based comparative genomic
hybridization technology to profile copy number
alterations in a series of 54 gliomas encompassing a
wide range of histopathological types and tumor
grades (Bredel et al. 2005). The third study analyzed
178 tumors for genomic alterations using the Affy-
metrix 100 K single-nucleotide polymorphism (SNP)
arrays (Kotliarov et al. 2006). For each alteration
identified in the aforementioned studies, BTECH
contains information on genomic localization and,
whenever possible, the number of times it has been
observed (Supplementary Table S3).
(iv) Genes of Interests
a. Tumor-related Genes
A series of genetic and epigenetic alterations occur
during tumor initiation and progression, some con-
ferring a growth advantage. Genes that are directly or
indirectly affected by such alterations are referred to
as tumor-related genes. We compiled a list of 3,432
tumor-related genes for inclusion in BTECH. These
include oncogenes, tumor suppressor genes and genes
whose altered expression has been associated with
tumor development, progression and/or metastasis.
The compiled list was derived from two resour-
ces: the NCBI database and the Affymetrix Human
Cancer Array HC-G110 (Affymetrix, http://www.
affymetrix.com/). First, we searched the “gene”
category of the NCBI database for the keyword
“tumor” or “cancer”. The NCBI database contains
information from the Online Mendelian Inheritance
inMan (OMIM), and provides a summary of known
functions for the genes within the database. This
resulted list contained a total of 3,223 genes of
which 214 were oncogenes, 57 were tumor suppres-
sor genes and the remainders were genes with altered
expression in tumors (as of September 30, 2010).
Next, we included 365 genes from the Affymetrix
Human Cancer Array HC-G110 (Affymetrix, http://
www.affymetrix.com/) that were represented in the
“known gene” table in the UCSC database.
62 Neuroinform (2011) 9:59–67
In addition, we generated a list of 242 genes that
have been reported to be specifically associated with
brain tumors, once again using the NCBI database.
In this case we searched the “gene” category using
the brain tumor names from the WHO grading
system. An annotation table for these 242 genes was
generated using the UCSC genome database and
subsequently included in BTECH.
b. Brain Tumor Differentially Expressed Genes
An initial search of PubMed for brain tumor
related large-scale gene expression studies revealed
twelve publications, eleven of which involving
microarrays (Ljubimova et al. 2001; Mariani et al.
2001; Park et al. 2003; Raza et al. 2004; Dong et al.
2005b; Fathallah-Shaykh 2005; Hoelzinger et al.
2005; Mehrian Shai et al. 2005; Kikuchi et al. 2006;
Bozinov et al. 2008; Rand et al. 2008), and one
based on SAGE analysis (Boon et al. 2002). All
genes identified in these studies as differentially
expressed were extracted for inclusion in BTECH.
For the SAGE-based study we extracted the genes
that were found to have a p-value of less than 0.05
after pair-wise comparisons between normal brain
and different types of brain tumors. A total of 544
differentially expressed genes were thus extracted, of
which 321 could be unambiguously mapped to
specific genomic loci. These 321 human genes were
included in the BTECH database, along with the
respective annotations regarding conditions under
which they were identified as differentially
expressed.
(v) Alu Elements
Almost half of the human genome is composed of
repetitive elements, which consist of interspersed
Fig. 1 An example of an Alu
element that shows lower meth-
ylation (yellow) in pediatric
ependymomas compared to nor-
mal brain controls, and the low-
est in recurrent tumors. This Alu
element resides in an intron of
the DNM2 gene. Datasets from
gene expression studies on pe-
diatric ependymomas indicate a
higher expression (red) of this
gene in tumor samples
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repeats and tandem repeats (Jordan et al. 2003). Alu
elements, as the most abundant short interspersed
nuclear elements, account for approximately 10% of
the human genome sequence (Kazazian 2004). Rather
than being passive bystanders in the human genome,
Alu elements play an active role in cancer predispo-
sition and development. Regions that have a high
density of Alu elements have been reported to be
associated with cancer-inducing chromosomal alter-
ations such as deletions, duplications, and transloca-
tions (Mauillon et al. 1996; Strout et al. 1998;
Kolomietz et al. 2001; Gad et al. 2002; Teugels et al.
2005; Abo-Dalo et al. 2010; Iskow et al. 2010). A
number of transcriptionally competent elements con-
tinue to amplify in the human genome by retrotrans-
position, thus leading to insertional polymorphism
(Batzer et al. 1995; Cordaux et al. 2007). Moreover,
Alu elements were shown to be associated with 5% of
the alternatively spliced internal exons in the human
genome (Lev-Maor et al. 2003). Approximately 8,000
Alus were predicted to have the potential to exonize
(Sorek et al. 2004). In the BTECH database, we
provide the annotations for all Alu elements in the
human genome (approximately 1.2 million) based on
the UCSC’s repeat masker table. In addition, we also
extracted the list of Alu elements that are polymorphic
with respect to integration in human populations
(Batzer et al. 1995; Cordaux et al. 2007), as well as
the list of Alu elements that are prone to becoming
exonized (Sorek et al. 2004),.
In addition to the genetic alterations that Alu elements
may cause, hypomethylation of Alu elements has been
Fig. 2 An integrative view of
brain tumor genomics, epige-
nomics, and transcriptomic data
using genome browser. Detailed
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shown to be strongly associated with cancer progression
and poor clinical outcome (Riggs and Jones 1983;
Feinberg and Tycko 2004; Cho et al. 2007; Estecio et
al. 2007; Roman-Gomez et al. 2008). In a recent
publication using a high-throughput sequencing-based
technique, we reported the methylation status of 31,178
Alu elements and their 5′ flanking sequences in normal
brain and in ependymomas of different grades (Xie et al.
2010). These data have been included in the BTECH
database, and retrievable from the genome browser listed
under category “Soares’ Lab Methylation Data” with
separate tracks for individual tumor samples (Fig. 1).
(vi) General Annotations
In addition to the molecular data and the selected
gene lists discussed above, BTECH also harbors
relevant genome annotations. The following genome
annotations were downloaded from the databases
indicated below:
& RefSeq mRNA, Entrez genes, three-frame transla-
tion, DNA recombination rates were downloaded
from UCSC genome database (human reference
sequence NCBI Build 36.1).
& CpG islands were identified by the program
described by Takai et al. (Takai and Jones 2002)
without masking the repetitive elements.
& SNP annotations were from dbSNP (http://www.
ncbi.nlm.nih.gov/SNP/, build 127)
& All microRNA elements were downloaded and
extracted from the Sanger Institute (http://www.
sanger.ac.uk/, release 14).
& Chromosome ideogram information was from
NCBI.
& Genomic sequences were based on human reference
sequence (NCBI Build 36.1).
Database Design and Implementation
The BTECH database has been installed on a Mac OS X
Server and is freely accessible through http://cmbteg.
childrensmemorial.org. The BTECH database consists of a
relational database hosted by the MySQL database manage-
ment system (http://www.mysql.com/). In addition, a ge-
nome browser has been installed to provide an integrated
interface for displaying experimental datasets and annota-
tions using the genome annotation viewer software compo-
nents from GMOD (Generic Model Organism Database
project) (Stein et al. 2002). The datasets displayed on the
Genome Browser were represented by different tracks. These
tracks are laid on top of the human genomic sequence, thus
enabling simultaneous visualization of all corresponding
molecular data, sequence features and annotations (Fig. 2).
From the genome browser, users can query the database
using gene names, symbols, Genbank accession numbers or
genomic co-ordinates.
Future Directions
The BTECH database is the first integrated molecular
database that has been designed specifically for brain tumor
studies. The database will be continuously updated and
expanded. Future development will be focusing on the
design of query engines for the database. Such query
engines would allow users to search against the vast amount of
brain tumor study datasets and provide efficient data mining.
In addition, we are also going to analyze various kinds of
alterations and develop hypotheses for a better understanding
of the molecular mechanisms underlying brain tumor
development and progression.
Information Sharing Statement
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